Press Releases

Press Releases
Date Title and Summary View
Aug 25, 2010 SUMMIT, N.J., Aug 25, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced that information was posted on the FDA Web site indicating that an Abbreviated New Drug Application (ANDA) has been received by the Office of Generic Drugs (OGD) containing a "Paragraph IV" patent certification, for REVL...
Aug 20, 2010 BOUDRY, Switzerland, Aug 20, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) a...
Aug 4, 2010 SUMMIT, N.J., Aug 04, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced that it has received verbal confirmation of early termination of the Hart-Scott-Rodino Act (HSR) 30-day waiting period without the United States Federal Trade Commission (FTC) requesting additional information with regar...
Jul 29, 2010 SUMMIT, N.J., Jul 29, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG): 2010 Second Quarter Financial Results Year-Over-Year Non-GAAP Total Revenue Increased 36 Percent to $850 Million; GAA...
Jul 19, 2010 SUMMIT, N.J., Jul 19, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, July 29, 2010 at 9 a.m. ET to discuss the company's second quarter 2010 financial and operational results. The webcast will be available in the inv...
Jun 30, 2010 SUMMIT, N.J. & LOS ANGELES, Jun 30, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG)and Abraxis BioScience Inc. (Nasdaq: ABII) today jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience. Under the terms of the merg...
Jun 24, 2010 (June 24, 2010) – Celgene International Sàrl (NASDAQ: CELG) announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan’s Ministry of Health, Labour and Welfare (MHLW) for use in combination with dexamethasone as a treatment for patients with relapsed or refract...
Jun 14, 2010 SUMMIT, N.J., Jun 14, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an overvi...
Jun 12, 2010 BOUDRY, Switzerland, Jun 12, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that data from the planned second interim analysis (median follow-up of 21 months) of a phase III, randomized, double-blind study of continuous REVLIMID (lenalidomide) for the treatment of elderly patients with new...
Jun 7, 2010 BOUDRY, Switzerland, Jun 07, 2010 (BUSINESS WIRE) --ABSTRACT #6508 Celgene International Sàrl (NASDAQ:CELG) today announced thatresearchers presented data from an investigator-initiated Phase II study of lenalidomide (REVLIMID) in untreated patients with chronic lymphocytic leukemia at the ann...
FirstPrevious ...
45
NextLast
Add to Briefcase = add release to Briefcase